BioSpace News Archive

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted to recommend CAPVAXIVE™ as an option for adults 65 years of age and older for pneumococcal vaccination.

Abbisko Therapeutics Co., Ltd. announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma（HCC）at the 2024 ESMO-GI Congress.

Dioseve Inc., aiming to develop assisted reproductive technology using oocytes derived from iPS cells, has raised 7 million USD.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”).

Oragenics, Inc. today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.

Gain Therapeutics, Inc. today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024.

Coherus BioSciences, Inc today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million.

The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024.

Tonix Pharmaceuticals Holding Corp. today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof).